| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 116 | 2024 | 638 | 13.840 |
Why?
|
| Carcinoma, Renal Cell | 105 | 2024 | 437 | 13.270 |
Why?
|
| Antineoplastic Agents | 94 | 2024 | 2415 | 5.870 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 70 | 2024 | 2566 | 4.740 |
Why?
|
| Urinary Bladder Neoplasms | 40 | 2024 | 401 | 4.110 |
Why?
|
| Prostatic Neoplasms | 62 | 2023 | 1769 | 3.770 |
Why?
|
| Angiogenesis Inhibitors | 24 | 2022 | 317 | 3.630 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 16 | 2024 | 121 | 3.430 |
Why?
|
| Carcinoma, Transitional Cell | 24 | 2019 | 171 | 3.080 |
Why?
|
| Protein Kinase Inhibitors | 22 | 2022 | 605 | 2.700 |
Why?
|
| Deoxycytidine | 27 | 2021 | 238 | 2.590 |
Why?
|
| Neoplasms | 30 | 2024 | 3041 | 2.450 |
Why?
|
| Urologic Neoplasms | 15 | 2021 | 84 | 2.390 |
Why?
|
| Neoplasm Metastasis | 53 | 2024 | 1109 | 2.330 |
Why?
|
| Pyrroles | 15 | 2021 | 187 | 1.990 |
Why?
|
| Indoles | 15 | 2016 | 314 | 1.960 |
Why?
|
| Pyridines | 18 | 2019 | 315 | 1.960 |
Why?
|
| Benzenesulfonates | 16 | 2012 | 66 | 1.950 |
Why?
|
| Molecular Targeted Therapy | 9 | 2023 | 286 | 1.850 |
Why?
|
| Humans | 320 | 2024 | 89357 | 1.820 |
Why?
|
| Aged | 170 | 2024 | 19165 | 1.780 |
Why?
|
| Niacinamide | 20 | 2016 | 117 | 1.720 |
Why?
|
| Clinical Trials as Topic | 20 | 2024 | 1150 | 1.700 |
Why?
|
| Phenylurea Compounds | 20 | 2016 | 115 | 1.690 |
Why?
|
| Male | 222 | 2024 | 42411 | 1.680 |
Why?
|
| Clinical Trials, Phase II as Topic | 16 | 2016 | 172 | 1.560 |
Why?
|
| Middle Aged | 173 | 2024 | 25974 | 1.560 |
Why?
|
| Aged, 80 and over | 90 | 2024 | 6811 | 1.500 |
Why?
|
| Neovascularization, Pathologic | 10 | 2021 | 364 | 1.430 |
Why?
|
| Treatment Outcome | 92 | 2024 | 8241 | 1.420 |
Why?
|
| Cisplatin | 21 | 2024 | 618 | 1.380 |
Why?
|
| Research Design | 15 | 2023 | 599 | 1.380 |
Why?
|
| Sirolimus | 8 | 2020 | 170 | 1.340 |
Why?
|
| Androgen Antagonists | 17 | 2022 | 154 | 1.290 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2016 | 3448 | 1.280 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2016 | 838 | 1.240 |
Why?
|
| Quinazolines | 9 | 2016 | 221 | 1.230 |
Why?
|
| Disease-Free Survival | 46 | 2021 | 1214 | 1.210 |
Why?
|
| Testosterone | 4 | 2018 | 276 | 1.180 |
Why?
|
| Contrast Media | 10 | 2016 | 1091 | 1.180 |
Why?
|
| Interferon-alpha | 12 | 2015 | 226 | 1.100 |
Why?
|
| Biomarkers, Tumor | 23 | 2022 | 1549 | 1.080 |
Why?
|
| Pyrimidines | 7 | 2022 | 374 | 1.070 |
Why?
|
| Gadolinium DTPA | 8 | 2013 | 264 | 1.060 |
Why?
|
| Survival Analysis | 39 | 2021 | 1534 | 1.050 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2021 | 1365 | 0.990 |
Why?
|
| Female | 141 | 2024 | 46202 | 0.970 |
Why?
|
| Adenocarcinoma | 17 | 2023 | 1194 | 0.950 |
Why?
|
| Antibodies, Monoclonal | 20 | 2019 | 1412 | 0.950 |
Why?
|
| Disease Progression | 32 | 2021 | 1489 | 0.940 |
Why?
|
| Bevacizumab | 21 | 2021 | 289 | 0.920 |
Why?
|
| Antineoplastic Agents, Hormonal | 12 | 2014 | 157 | 0.920 |
Why?
|
| Prostate-Specific Antigen | 24 | 2022 | 360 | 0.920 |
Why?
|
| Pharmacogenetics | 6 | 2019 | 443 | 0.890 |
Why?
|
| Neoplasm Staging | 28 | 2019 | 2018 | 0.890 |
Why?
|
| Adult | 104 | 2024 | 26607 | 0.860 |
Why?
|
| Antimetabolites, Antineoplastic | 10 | 2007 | 244 | 0.850 |
Why?
|
| Sulfonamides | 3 | 2016 | 318 | 0.850 |
Why?
|
| Interleukin-2 | 11 | 2008 | 251 | 0.820 |
Why?
|
| Fluorouracil | 10 | 2011 | 561 | 0.810 |
Why?
|
| Drug Administration Schedule | 30 | 2020 | 895 | 0.800 |
Why?
|
| Antibodies, Monoclonal, Humanized | 25 | 2021 | 969 | 0.740 |
Why?
|
| Health Expenditures | 1 | 2021 | 91 | 0.720 |
Why?
|
| Health Literacy | 1 | 2021 | 73 | 0.720 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 7 | 2023 | 72 | 0.720 |
Why?
|
| Vascular Endothelial Growth Factor A | 17 | 2023 | 424 | 0.710 |
Why?
|
| Imidazoles | 8 | 2016 | 148 | 0.700 |
Why?
|
| Societies, Scientific | 1 | 2020 | 43 | 0.690 |
Why?
|
| Conflict of Interest | 1 | 2020 | 68 | 0.690 |
Why?
|
| Vinblastine | 8 | 2015 | 108 | 0.660 |
Why?
|
| Urothelium | 9 | 2016 | 71 | 0.650 |
Why?
|
| Androstenes | 6 | 2021 | 45 | 0.650 |
Why?
|
| Prognosis | 29 | 2018 | 3783 | 0.640 |
Why?
|
| Quinolines | 5 | 2020 | 91 | 0.640 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2022 | 175 | 0.640 |
Why?
|
| Infusions, Intravenous | 19 | 2010 | 435 | 0.620 |
Why?
|
| Indazoles | 7 | 2021 | 67 | 0.620 |
Why?
|
| Survival Rate | 25 | 2020 | 1901 | 0.610 |
Why?
|
| Benzamides | 4 | 2024 | 237 | 0.610 |
Why?
|
| Everolimus | 5 | 2024 | 40 | 0.600 |
Why?
|
| Benzodioxoles | 2 | 2015 | 16 | 0.600 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2009 | 116 | 0.590 |
Why?
|
| Drug Design | 4 | 2007 | 127 | 0.590 |
Why?
|
| Doxorubicin | 9 | 2019 | 301 | 0.580 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2023 | 1942 | 0.570 |
Why?
|
| Drug Resistance, Neoplasm | 15 | 2020 | 618 | 0.560 |
Why?
|
| Carcinoma | 5 | 2012 | 443 | 0.560 |
Why?
|
| Prospective Studies | 23 | 2023 | 4289 | 0.550 |
Why?
|
| Castration | 4 | 2012 | 41 | 0.550 |
Why?
|
| Bone Neoplasms | 9 | 2016 | 329 | 0.550 |
Why?
|
| Methotrexate | 8 | 2015 | 250 | 0.550 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 159 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2001 | 86 | 0.530 |
Why?
|
| Patient Selection | 10 | 2023 | 684 | 0.530 |
Why?
|
| Double-Blind Method | 18 | 2022 | 1719 | 0.520 |
Why?
|
| Orchiectomy | 10 | 2016 | 72 | 0.510 |
Why?
|
| Administration, Oral | 16 | 2024 | 682 | 0.510 |
Why?
|
| Image Enhancement | 2 | 2009 | 567 | 0.480 |
Why?
|
| Immunotherapy | 8 | 2022 | 682 | 0.480 |
Why?
|
| Endpoint Determination | 6 | 2024 | 61 | 0.470 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2011 | 41 | 0.470 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2013 | 688 | 0.470 |
Why?
|
| Pteridines | 1 | 2013 | 5 | 0.460 |
Why?
|
| Nomograms | 2 | 2014 | 29 | 0.460 |
Why?
|
| Organoplatinum Compounds | 2 | 2005 | 97 | 0.460 |
Why?
|
| Proportional Hazards Models | 10 | 2024 | 851 | 0.450 |
Why?
|
| Quality of Life | 9 | 2021 | 1668 | 0.440 |
Why?
|
| Prostatectomy | 6 | 2012 | 477 | 0.430 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 385 | 0.430 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 6 | 2014 | 85 | 0.420 |
Why?
|
| Maximum Tolerated Dose | 9 | 2023 | 272 | 0.410 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 142 | 0.410 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2011 | 414 | 0.410 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 502 | 0.400 |
Why?
|
| Benzimidazoles | 4 | 2017 | 111 | 0.390 |
Why?
|
| Subtraction Technique | 2 | 2009 | 132 | 0.390 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 337 | 0.380 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2016 | 487 | 0.370 |
Why?
|
| Anilides | 4 | 2019 | 48 | 0.370 |
Why?
|
| Flavonoids | 3 | 2000 | 87 | 0.370 |
Why?
|
| Gene Expression Profiling | 10 | 2018 | 1431 | 0.370 |
Why?
|
| Combined Modality Therapy | 16 | 2024 | 1719 | 0.360 |
Why?
|
| Forecasting | 2 | 2009 | 306 | 0.360 |
Why?
|
| Models, Biological | 6 | 2013 | 1765 | 0.360 |
Why?
|
| Liver Neoplasms | 9 | 2021 | 758 | 0.350 |
Why?
|
| Depsipeptides | 2 | 2009 | 30 | 0.350 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2015 | 138 | 0.350 |
Why?
|
| Signal Transduction | 11 | 2019 | 3385 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2024 | 860 | 0.350 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2021 | 187 | 0.350 |
Why?
|
| Piperidines | 3 | 2000 | 166 | 0.350 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 3666 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 9 | 2024 | 576 | 0.340 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2004 | 160 | 0.340 |
Why?
|
| Capecitabine | 5 | 2024 | 98 | 0.340 |
Why?
|
| Cetuximab | 2 | 2020 | 117 | 0.340 |
Why?
|
| Salvage Therapy | 5 | 2012 | 236 | 0.340 |
Why?
|
| Pyrrolidinones | 2 | 2020 | 16 | 0.340 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2009 | 8 | 0.330 |
Why?
|
| Prostatic Hyperplasia | 1 | 2010 | 91 | 0.330 |
Why?
|
| Colorectal Neoplasms | 4 | 2012 | 981 | 0.330 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 344 | 0.320 |
Why?
|
| Antigens, Surface | 1 | 2009 | 103 | 0.320 |
Why?
|
| Pyrazines | 3 | 2006 | 94 | 0.320 |
Why?
|
| Naphthalenes | 3 | 2014 | 45 | 0.320 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 198 | 0.320 |
Why?
|
| Precision Medicine | 5 | 2023 | 410 | 0.320 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 144 | 0.310 |
Why?
|
| Cell Cycle Proteins | 4 | 2009 | 401 | 0.310 |
Why?
|
| Risk Assessment | 9 | 2016 | 2303 | 0.310 |
Why?
|
| Medical Oncology | 3 | 2024 | 383 | 0.310 |
Why?
|
| Cystectomy | 4 | 2024 | 110 | 0.310 |
Why?
|
| Nitriles | 4 | 2024 | 160 | 0.310 |
Why?
|
| Androgens | 2 | 2009 | 176 | 0.310 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 253 | 0.300 |
Why?
|
| Boronic Acids | 2 | 2006 | 56 | 0.290 |
Why?
|
| Epothilones | 1 | 2007 | 13 | 0.290 |
Why?
|
| Chicago | 7 | 2017 | 1427 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2019 | 196 | 0.290 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 179 | 0.290 |
Why?
|
| Urogenital Neoplasms | 2 | 2006 | 25 | 0.290 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 281 | 0.290 |
Why?
|
| Tubulin Modulators | 1 | 2007 | 24 | 0.290 |
Why?
|
| Chromosomes, Human | 1 | 2007 | 66 | 0.280 |
Why?
|
| Receptors, Androgen | 5 | 2024 | 123 | 0.280 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2024 | 131 | 0.280 |
Why?
|
| Phenylthiohydantoin | 2 | 2024 | 48 | 0.280 |
Why?
|
| Peptide Fragments | 1 | 2009 | 463 | 0.280 |
Why?
|
| Genes, p16 | 3 | 2001 | 11 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2001 | 290 | 0.280 |
Why?
|
| Apoptosis | 6 | 2005 | 1717 | 0.280 |
Why?
|
| Anxiety | 1 | 2009 | 308 | 0.280 |
Why?
|
| Photosensitivity Disorders | 1 | 2006 | 16 | 0.280 |
Why?
|
| Keratosis | 1 | 2006 | 21 | 0.270 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 42 | 0.270 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 154 | 0.270 |
Why?
|
| Cognition | 2 | 2010 | 580 | 0.270 |
Why?
|
| Cancer Vaccines | 3 | 2016 | 160 | 0.270 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 170 | 0.270 |
Why?
|
| Floxuridine | 2 | 2004 | 12 | 0.270 |
Why?
|
| Drug Eruptions | 1 | 2006 | 34 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2013 | 102 | 0.270 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2005 | 18 | 0.260 |
Why?
|
| Urinary Bladder | 3 | 2024 | 246 | 0.260 |
Why?
|
| Time Factors | 17 | 2016 | 5338 | 0.260 |
Why?
|
| Neoplasm Proteins | 2 | 2007 | 540 | 0.260 |
Why?
|
| Thalidomide | 2 | 2002 | 57 | 0.260 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2002 | 112 | 0.260 |
Why?
|
| Kidney | 3 | 2020 | 1147 | 0.260 |
Why?
|
| Chromosome Aberrations | 4 | 2006 | 390 | 0.260 |
Why?
|
| Enzyme Inhibitors | 5 | 2009 | 645 | 0.250 |
Why?
|
| Head and Neck Neoplasms | 3 | 2020 | 1063 | 0.240 |
Why?
|
| Indenes | 1 | 2024 | 10 | 0.240 |
Why?
|
| Ureteral Neoplasms | 1 | 2004 | 14 | 0.240 |
Why?
|
| Triazoles | 1 | 2005 | 102 | 0.240 |
Why?
|
| Chromosome Deletion | 5 | 2001 | 229 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2018 | 1265 | 0.240 |
Why?
|
| Interferon-gamma | 3 | 2016 | 451 | 0.240 |
Why?
|
| Cell Division | 4 | 2003 | 696 | 0.240 |
Why?
|
| Rare Diseases | 1 | 2004 | 70 | 0.230 |
Why?
|
| Ipilimumab | 2 | 2022 | 61 | 0.230 |
Why?
|
| Ambulatory Care | 2 | 2013 | 187 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 4 | 2015 | 669 | 0.230 |
Why?
|
| Mutation | 10 | 2021 | 4143 | 0.230 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 73 | 0.230 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.220 |
Why?
|
| Abducens Nerve Diseases | 1 | 2003 | 3 | 0.220 |
Why?
|
| Paralysis | 1 | 2003 | 22 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2014 | 72 | 0.220 |
Why?
|
| Rituximab | 3 | 2021 | 119 | 0.220 |
Why?
|
| Biomarkers | 7 | 2022 | 1767 | 0.220 |
Why?
|
| Taxoids | 6 | 2013 | 130 | 0.220 |
Why?
|
| Accreditation | 1 | 2013 | 62 | 0.210 |
Why?
|
| Genomics | 3 | 2021 | 762 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 7 | 2006 | 112 | 0.210 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 98 | 0.210 |
Why?
|
| Nuclear Proteins | 4 | 2000 | 726 | 0.210 |
Why?
|
| Mesothelioma | 3 | 2012 | 323 | 0.210 |
Why?
|
| Immunoenzyme Techniques | 3 | 2011 | 306 | 0.210 |
Why?
|
| Treatment Failure | 7 | 2011 | 287 | 0.210 |
Why?
|
| Prescription Drugs | 2 | 2021 | 36 | 0.210 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 30 | 0.200 |
Why?
|
| Homozygote | 3 | 2001 | 204 | 0.200 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 160 | 0.200 |
Why?
|
| Isotretinoin | 2 | 2000 | 23 | 0.200 |
Why?
|
| Quinolones | 4 | 2014 | 60 | 0.200 |
Why?
|
| Dacarbazine | 1 | 2002 | 102 | 0.200 |
Why?
|
| Chromosome Disorders | 2 | 2001 | 115 | 0.200 |
Why?
|
| Knowledge | 1 | 2021 | 29 | 0.200 |
Why?
|
| Thromboembolism | 1 | 2002 | 120 | 0.200 |
Why?
|
| Meningioma | 1 | 2022 | 63 | 0.200 |
Why?
|
| Meningeal Neoplasms | 1 | 2022 | 67 | 0.200 |
Why?
|
| Gene Deletion | 3 | 2001 | 342 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 5 | 2019 | 377 | 0.190 |
Why?
|
| Muscle Neoplasms | 1 | 2001 | 18 | 0.190 |
Why?
|
| Paclitaxel | 5 | 2009 | 479 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2001 | 354 | 0.190 |
Why?
|
| Faculty, Medical | 1 | 2013 | 186 | 0.190 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 16 | 0.190 |
Why?
|
| Diphosphonates | 2 | 2014 | 36 | 0.190 |
Why?
|
| Metaphase | 1 | 2000 | 25 | 0.180 |
Why?
|
| Cell Transformation, Viral | 2 | 2000 | 40 | 0.180 |
Why?
|
| G2 Phase | 1 | 2000 | 34 | 0.180 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 46 | 0.180 |
Why?
|
| Prednisone | 6 | 2019 | 259 | 0.180 |
Why?
|
| Retrospective Studies | 14 | 2021 | 9057 | 0.180 |
Why?
|
| Models, Statistical | 2 | 2015 | 576 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 125 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 10 | 1999 | 1057 | 0.180 |
Why?
|
| Peritoneal Neoplasms | 3 | 2012 | 184 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2009 | 261 | 0.170 |
Why?
|
| Hydrogen Peroxide | 1 | 2000 | 159 | 0.170 |
Why?
|
| Suramin | 3 | 2004 | 27 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 148 | 0.170 |
Why?
|
| Tumor Burden | 3 | 2013 | 308 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2002 | 228 | 0.170 |
Why?
|
| Sesquiterpenes | 1 | 1999 | 13 | 0.170 |
Why?
|
| Injections, Subcutaneous | 5 | 2008 | 125 | 0.170 |
Why?
|
| Receptor, EphB4 | 1 | 2019 | 24 | 0.170 |
Why?
|
| Cell Cycle | 2 | 1999 | 509 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 105 | 0.170 |
Why?
|
| Papillomaviridae | 2 | 2000 | 156 | 0.170 |
Why?
|
| Internal Medicine | 1 | 2013 | 355 | 0.170 |
Why?
|
| Algorithms | 1 | 2007 | 1877 | 0.170 |
Why?
|
| Kidney Pelvis | 2 | 2018 | 51 | 0.170 |
Why?
|
| Venae Cavae | 1 | 2019 | 13 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 2758 | 0.170 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 87 | 0.160 |
Why?
|
| Radiosurgery | 2 | 2013 | 288 | 0.160 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 20 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 393 | 0.160 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2009 | 92 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2017 | 2872 | 0.160 |
Why?
|
| Photochemotherapy | 1 | 1999 | 101 | 0.160 |
Why?
|
| Early Termination of Clinical Trials | 3 | 2013 | 16 | 0.160 |
Why?
|
| Fatigue | 7 | 2013 | 179 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2019 | 157 | 0.160 |
Why?
|
| Immunohistochemistry | 9 | 2014 | 1799 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2011 | 302 | 0.160 |
Why?
|
| Protein Kinase C | 1 | 1999 | 268 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 424 | 0.160 |
Why?
|
| T-Lymphocytes | 4 | 2016 | 1224 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 192 | 0.160 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 16 | 0.160 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2016 | 25 | 0.150 |
Why?
|
| Cystatin C | 1 | 2018 | 28 | 0.150 |
Why?
|
| Carrier Proteins | 3 | 1996 | 681 | 0.150 |
Why?
|
| Chromosome Mapping | 5 | 2006 | 1076 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 126 | 0.150 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2005 | 67 | 0.150 |
Why?
|
| Placebos | 4 | 2012 | 214 | 0.150 |
Why?
|
| Recombinant Proteins | 4 | 2009 | 1012 | 0.150 |
Why?
|
| Lung Neoplasms | 8 | 2013 | 2362 | 0.150 |
Why?
|
| Food | 1 | 2018 | 90 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2013 | 784 | 0.150 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2008 | 108 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.140 |
Why?
|
| United States | 11 | 2018 | 6989 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 58 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2019 | 170 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 200 | 0.140 |
Why?
|
| Disease Management | 3 | 2019 | 329 | 0.140 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1996 | 34 | 0.140 |
Why?
|
| Kallikreins | 2 | 2016 | 49 | 0.140 |
Why?
|
| Organophosphorus Compounds | 1 | 2016 | 55 | 0.140 |
Why?
|
| Diagnostic Imaging | 3 | 2016 | 479 | 0.140 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 20 | 0.130 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 2624 | 0.130 |
Why?
|
| Safety | 4 | 2010 | 149 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 2015 | 0.130 |
Why?
|
| Radiography | 3 | 2014 | 809 | 0.130 |
Why?
|
| Melanoma | 3 | 2004 | 468 | 0.130 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 134 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2016 | 463 | 0.130 |
Why?
|
| DNA Repair | 1 | 2017 | 362 | 0.130 |
Why?
|
| Animals | 16 | 2023 | 27371 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 177 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2002 | 1224 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 66 | 0.130 |
Why?
|
| Interleukin-4 | 1 | 1995 | 130 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 45 | 0.130 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 625 | 0.120 |
Why?
|
| Mice | 10 | 2023 | 11761 | 0.120 |
Why?
|
| Diarrhea | 4 | 2011 | 182 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 100 | 0.120 |
Why?
|
| Pelvic Neoplasms | 1 | 2015 | 45 | 0.120 |
Why?
|
| Sample Size | 3 | 2013 | 128 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2015 | 113 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 106 | 0.120 |
Why?
|
| Immunologic Factors | 1 | 2016 | 171 | 0.120 |
Why?
|
| Mitotane | 1 | 2014 | 2 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 793 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2005 | 207 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2012 | 156 | 0.120 |
Why?
|
| Cellular Senescence | 4 | 2000 | 103 | 0.120 |
Why?
|
| Genetic Markers | 2 | 2011 | 478 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 565 | 0.120 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2014 | 12 | 0.120 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2014 | 18 | 0.120 |
Why?
|
| Drug Therapy, Combination | 5 | 2019 | 784 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 246 | 0.120 |
Why?
|
| Imidazolidines | 2 | 2005 | 5 | 0.120 |
Why?
|
| Folic Acid Antagonists | 2 | 2008 | 19 | 0.120 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2014 | 18 | 0.120 |
Why?
|
| Universities | 3 | 2011 | 148 | 0.120 |
Why?
|
| Genome, Human | 1 | 2019 | 767 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 312 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 203 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2009 | 1097 | 0.110 |
Why?
|
| Sulindac | 2 | 2005 | 10 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2013 | 1045 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 225 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2002 | 277 | 0.110 |
Why?
|
| Young Adult | 7 | 2024 | 6312 | 0.110 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2024 | 22 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 220 | 0.110 |
Why?
|
| Confidence Intervals | 5 | 2016 | 225 | 0.110 |
Why?
|
| Sarcoma | 1 | 2015 | 220 | 0.110 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 370 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2014 | 269 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 1996 | 423 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2007 | 307 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 36 | 0.110 |
Why?
|
| src-Family Kinases | 2 | 2011 | 76 | 0.100 |
Why?
|
| Up-Regulation | 3 | 2016 | 727 | 0.100 |
Why?
|
| Probability | 3 | 2009 | 353 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1072 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2010 | 871 | 0.100 |
Why?
|
| Feasibility Studies | 5 | 2019 | 780 | 0.100 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2008 | 21 | 0.100 |
Why?
|
| Accidental Falls | 2 | 2011 | 51 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2011 | 14 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2005 | 890 | 0.100 |
Why?
|
| ROC Curve | 3 | 2010 | 781 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 601 | 0.100 |
Why?
|
| Benzoquinones | 1 | 2011 | 27 | 0.100 |
Why?
|
| Retinoblastoma Protein | 3 | 2006 | 67 | 0.100 |
Why?
|
| Nephrectomy | 4 | 2019 | 295 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2019 | 162 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 389 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2004 | 296 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2020 | 501 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2013 | 149 | 0.100 |
Why?
|
| Purine-Nucleoside Phosphorylase | 3 | 1996 | 23 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 47 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 548 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 53 | 0.090 |
Why?
|
| Frail Elderly | 2 | 2011 | 82 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2011 | 82 | 0.090 |
Why?
|
| Estramustine | 1 | 2010 | 1 | 0.090 |
Why?
|
| Risk Factors | 8 | 2016 | 5499 | 0.090 |
Why?
|
| Interferons | 2 | 2006 | 126 | 0.090 |
Why?
|
| Snake Venoms | 1 | 2010 | 10 | 0.090 |
Why?
|
| Hemofiltration | 1 | 2010 | 11 | 0.090 |
Why?
|
| Radioisotopes | 2 | 2023 | 45 | 0.090 |
Why?
|
| Health Resources | 1 | 2011 | 81 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 105 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 128 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 1999 | 111 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2012 | 2366 | 0.090 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2010 | 5 | 0.090 |
Why?
|
| Compassionate Use Trials | 1 | 2010 | 7 | 0.090 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2010 | 45 | 0.090 |
Why?
|
| Hemoglobinopathies | 1 | 2010 | 10 | 0.090 |
Why?
|
| Pleural Neoplasms | 1 | 2012 | 198 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2007 | 127 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 207 | 0.090 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 165 | 0.090 |
Why?
|
| Ketoconazole | 2 | 2013 | 26 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 51 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 39 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2009 | 29 | 0.090 |
Why?
|
| Reference Values | 2 | 2009 | 661 | 0.090 |
Why?
|
| North America | 1 | 2010 | 184 | 0.080 |
Why?
|
| Kidney Medulla | 1 | 2010 | 81 | 0.080 |
Why?
|
| MAP Kinase Kinase 7 | 2 | 2007 | 21 | 0.080 |
Why?
|
| Self Report | 1 | 2011 | 297 | 0.080 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 186 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 360 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 60 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2009 | 31 | 0.080 |
Why?
|
| HLA-A2 Antigen | 1 | 2009 | 31 | 0.080 |
Why?
|
| Phosphorylation | 4 | 2009 | 1132 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 2558 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2008 | 24 | 0.080 |
Why?
|
| Tuberculosis, Urogenital | 1 | 1988 | 3 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 887 | 0.080 |
Why?
|
| Lactoferrin | 1 | 2008 | 11 | 0.080 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2008 | 25 | 0.080 |
Why?
|
| Prostate | 1 | 2012 | 393 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2009 | 175 | 0.080 |
Why?
|
| Antitubercular Agents | 1 | 1988 | 54 | 0.080 |
Why?
|
| Interleukin-12 | 1 | 2009 | 109 | 0.080 |
Why?
|
| Epitopes | 1 | 2009 | 255 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 505 | 0.080 |
Why?
|
| Computational Biology | 1 | 2011 | 543 | 0.080 |
Why?
|
| Neoplasm Grading | 3 | 2015 | 374 | 0.080 |
Why?
|
| Physical Fitness | 1 | 2008 | 51 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2008 | 37 | 0.080 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 33 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 2008 | 68 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 84 | 0.080 |
Why?
|
| Registries | 2 | 2023 | 784 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2007 | 1096 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 988 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2008 | 337 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2009 | 213 | 0.070 |
Why?
|
| Liver | 2 | 2021 | 1208 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 533 | 0.070 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 144 | 0.070 |
Why?
|
| Bortezomib | 2 | 2006 | 82 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2401 | 0.070 |
Why?
|
| Incidence | 2 | 2004 | 1595 | 0.070 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2007 | 20 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 138 | 0.070 |
Why?
|
| Adolescent | 5 | 2013 | 9263 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 296 | 0.070 |
Why?
|
| Hypertension | 2 | 2010 | 745 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 92 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 3011 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2006 | 96 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2011 | 551 | 0.070 |
Why?
|
| Logistic Models | 1 | 2010 | 1213 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2016 | 1862 | 0.070 |
Why?
|
| Bryostatins | 1 | 2006 | 15 | 0.070 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2006 | 14 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 432 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2007 | 140 | 0.070 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 83 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1242 | 0.070 |
Why?
|
| Swainsonine | 1 | 2005 | 1 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1597 | 0.070 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2006 | 67 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 122 | 0.070 |
Why?
|
| Flutamide | 1 | 2005 | 4 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1047 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 127 | 0.070 |
Why?
|
| Carboplatin | 2 | 2009 | 312 | 0.060 |
Why?
|
| Placenta Growth Factor | 2 | 2021 | 72 | 0.060 |
Why?
|
| Dexamethasone | 2 | 2004 | 344 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2007 | 114 | 0.060 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 182 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2004 | 240 | 0.060 |
Why?
|
| Transplantation Conditioning | 2 | 2005 | 374 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2661 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 68 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 188 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2006 | 192 | 0.060 |
Why?
|
| Receptor Cross-Talk | 1 | 2004 | 34 | 0.060 |
Why?
|
| Carcinoma, Medullary | 1 | 2004 | 10 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 333 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 283 | 0.060 |
Why?
|
| B7-H1 Antigen | 2 | 2016 | 274 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 65 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2000 | 43 | 0.060 |
Why?
|
| Scandium | 1 | 2023 | 5 | 0.060 |
Why?
|
| Anorexia | 2 | 2001 | 30 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2004 | 302 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 82 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 88 | 0.060 |
Why?
|
| Arteries | 1 | 2004 | 180 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 106 | 0.060 |
Why?
|
| Cell Line | 3 | 1999 | 2496 | 0.060 |
Why?
|
| Lymphocytes | 3 | 2016 | 471 | 0.060 |
Why?
|
| Camptothecin | 1 | 2004 | 196 | 0.060 |
Why?
|
| Paresthesia | 1 | 2003 | 16 | 0.050 |
Why?
|
| Pharynx | 1 | 2003 | 45 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 172 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 135 | 0.050 |
Why?
|
| Larynx | 1 | 2003 | 38 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 134 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2003 | 117 | 0.050 |
Why?
|
| Glutaminase | 1 | 2022 | 12 | 0.050 |
Why?
|
| Life Tables | 1 | 2002 | 48 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 433 | 0.050 |
Why?
|
| Integrin alphaXbeta2 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glutamates | 1 | 2022 | 89 | 0.050 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2022 | 10 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2022 | 4 | 0.050 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2002 | 118 | 0.050 |
Why?
|
| Glutamine | 1 | 2022 | 80 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2014 | 73 | 0.050 |
Why?
|
| Mifepristone | 1 | 2022 | 34 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2022 | 29 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 683 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2006 | 333 | 0.050 |
Why?
|
| Phenotype | 3 | 2016 | 2440 | 0.050 |
Why?
|
| DNA, Neoplasm | 3 | 2003 | 268 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2002 | 74 | 0.050 |
Why?
|
| Neutropenia | 2 | 2018 | 216 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2002 | 217 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2001 | 16 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 764 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2001 | 49 | 0.050 |
Why?
|
| Aneuploidy | 1 | 2001 | 57 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2002 | 98 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2001 | 56 | 0.050 |
Why?
|
| Lymphokines | 1 | 2021 | 76 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2001 | 109 | 0.050 |
Why?
|
| Acute Disease | 1 | 2003 | 841 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 150 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 468 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2000 | 7 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 73 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2000 | 32 | 0.050 |
Why?
|
| Biopsy | 2 | 2016 | 1184 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2016 | 371 | 0.050 |
Why?
|
| Watchful Waiting | 1 | 2021 | 63 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2001 | 94 | 0.050 |
Why?
|
| Remission Induction | 2 | 2000 | 740 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2021 | 245 | 0.050 |
Why?
|
| Cyclins | 1 | 2000 | 83 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 155 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 80 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 360 | 0.040 |
Why?
|
| Asthenia | 1 | 2000 | 4 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 57 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 119 | 0.040 |
Why?
|
| Steroids | 1 | 2021 | 174 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 275 | 0.040 |
Why?
|
| Endothelium | 1 | 2000 | 58 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2003 | 922 | 0.040 |
Why?
|
| Cyclohexanes | 1 | 1999 | 9 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 573 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 739 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Fever | 1 | 2000 | 128 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2002 | 279 | 0.040 |
Why?
|
| Rats | 4 | 2005 | 4041 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 657 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 112 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 667 | 0.040 |
Why?
|
| Abiraterone Acetate | 1 | 2018 | 12 | 0.040 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1998 | 18 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 1998 | 53 | 0.040 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 1998 | 20 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 691 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 84 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2002 | 449 | 0.040 |
Why?
|
| Cell Death | 1 | 1999 | 262 | 0.040 |
Why?
|
| Sex Distribution | 1 | 1998 | 171 | 0.040 |
Why?
|
| Singapore | 1 | 2018 | 16 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 206 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2007 | 1120 | 0.040 |
Why?
|
| Age Distribution | 1 | 1998 | 200 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2000 | 389 | 0.040 |
Why?
|
| Gallium | 1 | 1998 | 4 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 1998 | 54 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 1998 | 129 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 49 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 302 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 200 | 0.040 |
Why?
|
| Ifosfamide | 1 | 1998 | 49 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 511 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2005 | 695 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2000 | 382 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 266 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2017 | 25 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1998 | 29 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2008 | 90 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 69 | 0.040 |
Why?
|
| Research Subjects | 1 | 1998 | 73 | 0.040 |
Why?
|
| Research | 1 | 2019 | 252 | 0.040 |
Why?
|
| Restriction Mapping | 2 | 1995 | 156 | 0.040 |
Why?
|
| Fasting | 1 | 2018 | 163 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2000 | 458 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 77 | 0.040 |
Why?
|
| Cell Survival | 1 | 2000 | 983 | 0.040 |
Why?
|
| Lymphatic Vessels | 1 | 2018 | 69 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Tosyl Compounds | 2 | 2008 | 15 | 0.040 |
Why?
|
| Beta Particles | 1 | 2016 | 5 | 0.040 |
Why?
|
| MAP Kinase Kinase 6 | 2 | 2007 | 12 | 0.040 |
Why?
|
| Thrombosis | 1 | 2000 | 302 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 275 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1243 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 111 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 665 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 215 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 1996 | 31 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2016 | 8 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Infant | 1 | 2023 | 3160 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2016 | 98 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2016 | 58 | 0.030 |
Why?
|
| CD27 Ligand | 1 | 2015 | 1 | 0.030 |
Why?
|
| Patient Participation | 1 | 1998 | 224 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 24 | 0.030 |
Why?
|
| Urinary Tract | 1 | 1996 | 35 | 0.030 |
Why?
|
| Receptors, IgE | 1 | 1995 | 7 | 0.030 |
Why?
|
| Gossypol | 1 | 2015 | 6 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 40 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2016 | 73 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 42 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1998 | 307 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 358 | 0.030 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1995 | 37 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 222 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 73 | 0.030 |
Why?
|
| Informed Consent | 1 | 1998 | 275 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2008 | 299 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 193 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 460 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 179 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 131 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1995 | 22 | 0.030 |
Why?
|
| Proteins | 1 | 2000 | 787 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 171 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2014 | 20 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 374 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1723 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 1994 | 74 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 266 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 646 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 537 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 356 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 1996 | 2884 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 856 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 71 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 35 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 80 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 308 | 0.030 |
Why?
|
| Genes, ras | 1 | 2013 | 98 | 0.030 |
Why?
|
| Multigene Family | 1 | 1994 | 203 | 0.030 |
Why?
|
| Telomere | 1 | 1994 | 114 | 0.030 |
Why?
|
| Growth Substances | 1 | 1993 | 80 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 233 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 131 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 529 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2005 | 198 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 192 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2013 | 120 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2008 | 794 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2012 | 70 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2005 | 261 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 306 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2005 | 698 | 0.030 |
Why?
|
| United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
| Graft vs Host Disease | 2 | 2006 | 360 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1993 | 289 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2011 | 16 | 0.020 |
Why?
|
| Leucovorin | 1 | 1992 | 224 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2011 | 14 | 0.020 |
Why?
|
| Selection Bias | 1 | 2011 | 37 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1994 | 284 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 37 | 0.020 |
Why?
|
| Transfection | 2 | 2005 | 911 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 60 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2011 | 89 | 0.020 |
Why?
|
| Transplantation, Homologous | 2 | 2005 | 996 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 181 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 127 | 0.020 |
Why?
|
| Xylenes | 1 | 2010 | 5 | 0.020 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2010 | 15 | 0.020 |
Why?
|
| Bone Marrow | 2 | 2003 | 445 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2011 | 226 | 0.020 |
Why?
|
| Membranes, Artificial | 1 | 2010 | 39 | 0.020 |
Why?
|
| Iohexol | 1 | 2010 | 25 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 85 | 0.020 |
Why?
|
| Base Sequence | 3 | 2003 | 2327 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 712 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2005 | 815 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 231 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2003 | 2017 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2009 | 31 | 0.020 |
Why?
|
| Canada | 1 | 2010 | 208 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 3027 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 108 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 1157 | 0.020 |
Why?
|
| Polymers | 1 | 2010 | 194 | 0.020 |
Why?
|
| Mucositis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2009 | 31 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2008 | 45 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 66 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 27 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 26 | 0.020 |
Why?
|
| Paxillin | 1 | 2008 | 59 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 433 | 0.020 |
Why?
|
| Artifacts | 1 | 2010 | 247 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2008 | 8 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 38 | 0.020 |
Why?
|
| Goserelin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 470 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2009 | 176 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2007 | 20 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 466 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 4 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 176 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 261 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2007 | 24 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 151 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2007 | 60 | 0.020 |
Why?
|
| Pentoxifylline | 2 | 1998 | 9 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 899 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1996 | 1976 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 313 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2340 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2009 | 305 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2006 | 25 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Mannosidases | 1 | 2005 | 2 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 2005 | 22 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 209 | 0.020 |
Why?
|
| Weight Loss | 1 | 2007 | 227 | 0.020 |
Why?
|
| Epithelium | 2 | 1998 | 325 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2009 | 900 | 0.020 |
Why?
|
| Motor Activity | 1 | 2007 | 327 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2005 | 27 | 0.020 |
Why?
|
| Propionates | 1 | 2005 | 34 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2005 | 66 | 0.020 |
Why?
|
| Siblings | 1 | 2005 | 111 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 77 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 971 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 323 | 0.010 |
Why?
|
| Biological Availability | 1 | 2004 | 92 | 0.010 |
Why?
|
| Gene Library | 1 | 2004 | 133 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 269 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2004 | 144 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 1574 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 71 | 0.010 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.010 |
Why?
|
| Anemia | 1 | 2004 | 130 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 275 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2006 | 575 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 226 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2004 | 302 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 803 | 0.010 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 82 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 1144 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 62 | 0.010 |
Why?
|
| Illinois | 1 | 2003 | 480 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 1714 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 630 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2006 | 945 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 86 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2001 | 83 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 2001 | 47 | 0.010 |
Why?
|
| Glucuronates | 1 | 2000 | 22 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2001 | 92 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 3218 | 0.010 |
Why?
|
| Lactones | 1 | 2000 | 27 | 0.010 |
Why?
|
| Macrolides | 1 | 2000 | 31 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2000 | 273 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 975 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 414 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 392 | 0.010 |
Why?
|
| Biotransformation | 1 | 1998 | 50 | 0.010 |
Why?
|
| Antibodies | 1 | 2000 | 353 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1997 | 61 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 200 | 0.010 |
Why?
|
| Comprehension | 1 | 1998 | 81 | 0.010 |
Why?
|
| Personal Autonomy | 1 | 1998 | 116 | 0.010 |
Why?
|
| Disclosure | 1 | 1998 | 110 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 146 | 0.010 |
Why?
|
| Light | 1 | 1998 | 292 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2000 | 494 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1996 | 39 | 0.010 |
Why?
|
| Cystoscopy | 1 | 1996 | 39 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1996 | 168 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 135 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 418 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 543 | 0.010 |
Why?
|
| Lung | 1 | 1999 | 1263 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2062 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1995 | 825 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1995 | 689 | 0.010 |
Why?
|
| Gene Expression | 1 | 1995 | 1310 | 0.010 |
Why?
|